<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640405</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-12-01</org_study_id>
    <secondary_id>2012-000846-37</secondary_id>
    <nct_id>NCT01640405</nct_id>
  </id_info>
  <brief_title>Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells</brief_title>
  <acronym>VISNU-1</acronym>
  <official_title>Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab
      as first line treatment of patients with metastatic colorectal cancer not previously treated
      and with three or more circulating tumoral cells.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radical Resection (R0) surgery rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumour Cells (CTC) count basal and correlate to PFS, OS, RR</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of RAS, BRAF and PI3K mutations and clinical anti-tumour activity outcome ( PFS, OS, RR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>modified FOLFOX6 + bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOXIRI+bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modified FOLFOX6 + bevacizumab</intervention_name>
    <description>Bevacizumab 5 mg/kg iv, day 1, followed by
Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by
5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:
LV 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI + Bevacizumab</intervention_name>
    <description>Bevacizumab 5 mg/kg iv, followed by
Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by
Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by
LV 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient's Informed consent in written.

          2. Age between 18 and 70 years old.

          3. Eastern Cooperative Oncology group performance status (ECOG) 0-1.

          4. Life expectancy of at least 3 months.

          5. Histological confirmation of adenocarcinoma of the colon or rectum.

          6. To be included in the study patients should present &gt; or equal 3 CTC in peripheral
             blood.

          7. Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion
             following Response Evaluation Criteria In Solid Tumors (RECIST) criteria v 1.1 (non
             suitable for radical surgery at the inclusion time).

          8. Prior radiotherapy is allowed but must be completed at least 4 weeks before
             randomization (if applicable).

          9. Adequate bone marrow, liver and renal function.

         10. Women of childbearing potential must have a negative serum or urine pregnancy test.
             Postmenopausal women must have been amenorrheic for at least 12 months.Both men and
             women participating in this study must use adequate contraception.

         11. Subject must have the ability, in the opinion of the investigator, to comply with all
             the study procedures and follow-up examinations.

        Exclusion Criteria:

          1. Previous chemotherapy for metastatic disease.

          2. Prior treatment with Bevacizumab, or Epidermal Growth Factor Reception (EGFR)
             inhibitors

          3. Any anticancer treatment (chemotherapy, hormonal treatment, radiation treatment,
             surgery , immunotherapy, biologic therapy or tumour embolization) within 4 weeks
             before randomization.

          4. Use of any investigational drug within 4 weeks before start the treatment

          5. Clinical or radiographic evidence of brain metastasis.

          6. Uncontrolled hypertension (systolic blood pressure &gt; 150 mmHg and/or diastolic blood
             pressure &gt; 100 mmHg on repeated measurement) despite optimal medical management.

          7. Previous history of hypertensive encephalopathy or hypertensive crises.

          8. Current or history of peripheral neuropathy &gt; or equal to 1 National Cancer
             Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE).

          9. Patients classified as fragile according to criteria listed in the protocol.

         10. Significant cardiovascular disease (e.g. cerebrovascular accident (CVA), myocardial
             infarction, within 6 months before randomization). Unstable angina, congestive heart
             failure New York Heart Association (NYHA) ≥ class II, arrhythmia that requires
             treatment within 3 months before randomization.

         11. Significant vascular disease (e.g. aortic aneurism requiring surgical intervention,
             pulmonary embolic, peripheral arterial thrombosis) within 6 months before
             randomization.

         12. Previous history of significant haemorrhage /severe, within 1 month before
             randomization.

         13. Major surgery, open surgical biopsy or significant traumatic injury within 4 weeks
             before randomization.

         14. Large bore needle biopsy of a major organ within 14 days before randomization.
             Placement of central venous access port &gt; or equal to 7 days before randomization is
             permitted

         15. Evidence or history of bleeding diathesis or coagulopathy.

         16. International Normalized Ratio (INR) &gt; 1.5 within 14 days prior to starting study
             treatment. EXEMPTION: patients on full anticoagulation must have an in-range INR
             [usually between 2-3]. Any anticoagulation therapy must be at stable dosing prior to
             enrollment.

         17. History of previous abdominal fistula or gastrointestinal perforation within 6 months
             before randomization.

         18. Serious non-healing wound, ulcer or bone fracture.

         19. Acute or sub-acute of intestinal occlusion or history of intestinal inflammatory
             disease.

         20. History of uncontrolled convulsive crises.

         21. History of pulmonary fibrosis, acute lung disease or interstitial pneumonia.

         22. Chronic, actual o recent use (10 days prior first drug administration) of
             acetylsalicylic acic (aspirin) &gt; 325 mg/day or clopidogrel (75mg/day) or other
             treatments that can cause gastrointestinal ulcer (low-dose aspirin is permitted &lt; or
             equal to 325 mg/day).

         23. Urinary protein excretion &gt; or equal to 2+ (dipstick). If &gt; or equal 2 g proteinuria
             is detected with dipstick, a 24-hour period urine test will be performed and the
             result should be &lt; or equal to 1 g/24 hours to permit the inclusion of the patient in
             the clinical trial.

         24. Known human immunodeficiency virus infection or chronic hepatitis B or C infection or
             other uncontrolled, severe concurrent infection .

         25. Current infection &gt; or equal to Grade 2 (NCI-CTCAE).

         26. Any previous or concurrent cancer different to colorectal carcinoma within 5 years
             before to start the treatment. Subjects with successfully treated, non-invasive
             cancers, including cervical cancer in situ, basal cell carcinoma will be allowed to
             participate in the clinical trial. Or those cancer treated with curative intention
             without disease evidence in the last 5 years at least.

         27. Known or suspected allergy or hypersensitivity to any component of Bevacizumab,
             oxaliplatin, irinotecan, or 5-FU/LV.

         28. Any medical, psychological, or social condition that may interfere with the subject's
             participation in the study or evaluation of the study results.

         29. Any psychological, familial or geographic situation that interferes in the adequate
             follow.up and adherence to the study protocol.

         30. Women who are pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Díaz-Rubio, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Aranda, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Sastre, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Digestive Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>FOLFOXIRI</keyword>
  <keyword>circulating tumor cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

